Chronic pharmacological preconditioning against ischemia

Clinical Hemorheology and Microcirculation

Volumn 49, Issue 1-4, 2011, Pages 287-293

  Luca, Mary Clare ^a,b   Liuni, Andrew ^a,b   Muxel, Selina ^c   Münzel, Thomas ^c   Forconi, Sandro ^d   Gori, Tommaso ^c   Parker, John D ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^d UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 6 N CYCLOPENTYLADENOSINE; ADENOSINE A1 RECEPTOR; ATORVASTATIN; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MORPHINE; NITRATE; OPIATE; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ANGINA PECTORIS; BLOOD RHEOLOGY; CONFERENCE PAPER; DRUG EFFECT; HEART DEATH; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; ISCHEMIC PRECONDITIONING; NONHUMAN;

ADENOSINE; ANIMALS; CARDIOTONIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MICE; MORPHINE; MYOCARDIAL INFARCTION; NITRIC OXIDE SYNTHASE TYPE II; NITROGLYCERIN; RATS; SWINE;

EID: 84856824184     PISSN: 13860291     EISSN: 18758622     Source Type: Journal    
DOI: 10.3233/CH-2011-1479     Document Type: Conference Paper

References (57)

1. N. Abegunewardene, K.-H. Schmidt, M. Vosseler, K.-F. Kreitner, L.M. Schreiber, H.-A. Lehr, T. Gori, T. M̈unzel and G. Horstick, Gene therapy with iNOS enhances regional contractility and reduces delayed contrast enhancement in a model of postischemic congestive heart failure, Clin Hemorheol Microcirc, 49 (2011), 271-278.
2. Anonymous, Principles of ethical authorship for publication in clinical hemorheology and microcirculation, Clin Hemorheo Microcirc 43 (2009), 189-199.
3. J. Bhavsar and R.S. Rosenson, Adenosine transport, erythrocyte deformability and microvascular dysfunction: An unrecognized potential role for dipyridamole therapy, Clin Hemorheol Microcirc 44 (2010), 193-205.
4. R. Bolli, The late phase of preconditioning, Circ Res 87 (2000), 972-983.
5. R. Bolli, K. Shinmura, X.-L. Tang, E. Kodani, Y. Xuan, Y. Guo and B. Dawn, Discovery of a new function of cyclooxygenase(COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning, Cardiovasc Res 55 (2002), 506-519. (Pubitemid 34874945)
6. C. Chen, G. Budas, E. Churchill, M. Disatnik, T. Hurley and D. Mochly-Rosen, Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart, Science 321 (2008), 1493-1495.
7. A. Crisafulli, F. Melis, F. Tocco, U.M. Santoboni, C. Lai, G. Angioy, L. Lorrai, G. Pittau, A. Concu and P. Pagliaro, Exercise-induced and nitroglycerin-induced myocardial preconditioning improves hemodynamics in patients with angina, Am J Physiol Heart Circ Physiol 287 (2004), H235-H242. (Pubitemid 38802358)
8. T. Csont, Z. Szilvassy, F. Fulop, S. Nedeianu, T. Pali, A. Tosaki, L. Dux and P. Ferdinandy, Direct myocardial anti-schaemic effect of GTN in both nitrate-tolerant and nontolerant rats: A cyclic GMP-independent activation of KATP, Br J Pharmacol 128 (1999), 1427-1434.
9. B. Dawn and R. Bolli, Role of nitric oxide in myocardial preconditioning, Ann N Y Acad Sci 962 (2002), 18-41. (Pubitemid 34592297)
10. C. Depre, J.Y. Park, Y.T. Shen, X. Zhao, H. Qiu, L. Yan, B. Tian, S.F. Vatner and D.E. Vatner, Molecular mechanisms mediating preconditioning following chronic ischemia differ from those in classical second window, Am J Physiol Heart Circ Physiol 299 (2010), H752-H762.
11. P. Di Napoli, A.A. Taccardi, A. Grilli, M.A. De Lutiis, A. Barsotti, M. Felaco and R. De Caterina, Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts, Cardiovasc Res 66 (2005), 462-471. (Pubitemid 40725758)
12. G. Di Sciascio, G. Patti, V. Pasceri, A. Gaspardone, G. Colonna and A. Montinaro, Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: Results of theARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized trial, J Am Coll Cardiol 54 (2009), 558-565.
13. Z. Ebrahim, D.M. Yellon and G.F. Baxter, Attenuated cardioprotective response to bradykinin, but not classical ischaemic preconditioning, in DOCA-salt hypertensive left ventricular hypertrophy, Pharmacol Res 55 (2007), 42-48. (Pubitemid 46108586)
14. S. Ghosh, N.B. Standen and M. Galinanes, Preconditioning the human myocardium by simulated ischemia: Studies on the early and delayed protection, Cardiovasc Res 45 (2000), 339-350. (Pubitemid 30069499)
15. Z. Giricz, M.M. Lalu, C. Csonka, P. Bencsik, R. Schulz and P. Ferdinandy, Hyperlipidemia attenuates the infarct izelimiting effect of ischemic preconditioning: Role of matrix metalloproteinase-2 inhibition, J Pharmacol Exp Ther 316 (2006), 154-161. (Pubitemid 41832592)
16. T. Gori, G. Di Stolfo, S. Dragoni, M. Lisi, M.C. Leone, S. Forconi and J.D. Parker, The mechanism of nitrate-induced preconditioning, Clin Hemorheol Microcirc 39 (2008), 191-196. (Pubitemid 352039996)
17. T. Gori, G. Di Stolfo, S. Sicuro, S. Dragoni, M. Lisi, S. Forconi and J.D. Parker, Nitroglycerin protects the endothelium from ischaemia and reperfusion: Human mechanistic insight, Br J Clin Pharmacol 64 (2007), 145-150. (Pubitemid 47063243)
18. T. Gori, S. Dragoni, G. Di Stolfo, S. Sicuro, A. Liuni, M.C. Luca, G.R. Thomas, M. Oelze, A. Daiber and J.D. Parker, 'Tolerance' to Nitroglycerin- induced preconditioning of the endothelium: A human in vivo study, Am J Physiol Heart Circ Physiol 298 (2010), H340-H345.
19. S. Grotti and T. Gori, Endothelium, ischemia and the good side of oxygen free radicals, Clin Hemorheol Microcirc 39 (2008), 197-203. (Pubitemid 352039997)
20. Y. Guo,W.K. Jones, Y.T. Xuan, X.L. Tang,W. Bao,W.J.Wu, H. Han, V.E. Laubach, P. Ping, Z. Yang, Y. Qiu and R. Bolli, The late phase of ischemic preconditioning is abrogated by targeted disruption of the inducible NO synthase gene, Proc Natl Acad Sci U S A 96 (1999), 11507-11512. (Pubitemid 29487411)
21. D.J. Hausenloy and D.M. Yellon, Survival kinases in ischemic preconditioning and ostconditioning, Cardiovasc Res 70 (2006), 240-253.
22. D.B. Hazer,M. Berker, F. Narin, E. Ileri-Gurel, A.T. Basak, N. Seringec, F. Kaymaz, N. Dikmenoglu and M. Tuncel, Effects of pravastatin on cellular ultrastructure and hemorheology in rats after traumatic head injury, Clin Hemorheol Microcirc 46 (2010), 1-11.
23. M. Hill, H. Takano, X.L. Tang, E. Kodani, G. Shirk and R. Bolli, Nitroglycerin induces late preconditioning against myocardial infarction in conscious rabbits despite development of nitrate tolerance, Circulation 104 (2001), 694-699. (Pubitemid 32738525)
24. K. Ichihara, K. Satoh and Y. Abiko, Influences of pravastatin and simvastatin, HMG-CoA reductase inhibitors, on myocardial stunning in dogs, J Cardiovasc Pharmacol 22 (1993), 852-856. (Pubitemid 23360408)
25. M. Ishihara, I. Inoue, T. Kawagoe, Y. Shimatani, S. Kurisu, K. Nishioka, Y. Kouno, T. Umemura, S. Nakamura and H. Sato, Diabetes mellitus prevents ischemic preconditioning in patients with a first acute anterior wall myocardial infarction, J Am Coll Cardiol 38 (2001), 1007-1011. (Pubitemid 32912703)
26. M. Ishihara, H. Sato, H. Tateishi, T. Kawagoe, Y. Shimatani, S. Kurisu, K. Sakai and K. Ueda, Implications of prodromal angina pectoris in anterior wall acute myocardial infarction: Acute angiographic findings and long-term prognosis, J Am Coll Cardiol 30 (1997), 970-975. (Pubitemid 27435889)
27. A. Jabs, F. Fasola, S. Muxel, T. M̈unzel and T. Gori, Ischemic and non-ischemic preconditioning: Endothelium-focused translation into clinical practice, Clin Hemorheol Microcirc 45 (2010), 185-191.
28. G. Jancso, B. Cserepes, B. Gasz, L. Benko, A. Ferencz, B. Borsiczky, J. Lantos, A. Dureja, K. Kiss, J. Szeberenyi and E. Roth, Effect of acetylsalicylic acid on nuclear factor-kappaB activation and on late preconditioning against infarction in the myocardium, J Cardiovasc Pharmacol 46 (2005), 295-301. (Pubitemid 41262831)
29. H. Jneid, M. Leessar and R. Bolli, Cardiac preconditioning during percutaneous coronary interventions, Cardiovasc Drugs Ther 19 (2005), 211-217. (Pubitemid 41258137)
30. F. Jung, C. Mrowietz, C. Labarrere, S. Schuler and J.W. Park, Primary cutaneous microangiopathy in heart recipients, Microvasc Res 62 (2001), 154-163. (Pubitemid 32885702)
31. H.L. Lazar, Y. Bao, Y. Zhang and S.A. Bernard, Pretreatment with statins enhances myocardial protection during coronary revascularization, J Thorac Cardiovasc Surg 125 (2003), 1037-1042. (Pubitemid 36644880)
32. M.A. Leesar, M.F. Stoddard, B. Dawn, V.G. Jasti, R. Masden and R. Bolli, Delayed preconditioning-mimetic action of nitroglycerin in patients undergoing coronary angioplasty, Circulation 103 (2001), 2935-2941. (Pubitemid 32578131)
33. Q. Li, Y. Guo,W. Tan, A. Stein, B. Dawn,W.Wu, X. Zhu, X. Lu, X. Xu, T. Siddiqui, S. Tiwari and R. Bolli, Gene therapy with iNOS provides long-term protection against myocardial infarction without adverse functional consequences, Am J Physiol Heart Circ Physiol 290 (2006), H584-H589.
34. A. Liuni, M.C. Luca, T. Gori and J.D. Parker, Rosuvastatin prevents conduit artery endothelial dysfunction induced by ischemia and reperfusion by a cyclooxygenase-2-dependent mechanism, J Am Coll Cardiol 55 (2010), 1002-1006.
35. A. Liuni, M.C. Luca, T. Gori and J.D. Parker, The endothelial-protective effects of HMG-CoA reductase inhibition in the setting of ischemia and reperfusion injury, Clin Hemorheol Microcirc 45 (2010), 161-167.
36. M. Loubani, A. Fowler, N.B. Standen and M. Galinanes, The effect of gliclazide and glibenclamide on preconditioning of the human myocardium, Eur J Pharmacol 515 (2005), 142-149. (Pubitemid 40779279)
37. K. Mensah, M. Mocanu and D.M. Yellon, Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: A potential role for phosphatase and tensin homolog deleted on chromosome ten? J Am Coll Cardiol 45 (2005), 1287-1291. (Pubitemid 40523151)
38. C.E. Murry, R.B. Jennings and K.A. Reimer, Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium, Circulation 74 (1986), 1124-1136. (Pubitemid 17174962)
39. J. Neckar, B. Ostadal and F. Kolar, Myocardial infarct size-limiting effect of chronic hypoxia persists for five weeks of normoxic recovery, Physiol Res 53 (2004), 621-628. (Pubitemid 40065691)
40. C.E. Papadopoulos, H.I. Karvounis, G.E. Parharidis and G.E. Louridas, Multiple episodes of ischemic preconditioning are not associated with loss of benefit: Preliminary clinical experience, Can J Cardiol 21 (2005), 1291-1295. (Pubitemid 43174611)
41. J.N. Peart and G.J. Gross, Chronic exposure to morphine produces a marked cardioprotective phenotype in aged mouse hearts, Exp Gerontol 39 (2004), 1021-1026. (Pubitemid 38952882)
42. J.N. Peart and G.J. Gross, Morphine-tolerant mice exhibit a profound and persistent cardioprotective phenotype, Circulation 109 (2004), 1219-1222. (Pubitemid 38372779)
43. J.N. Peart and J.P. Headrick, Sustained cardioprotection: Exploring unconventional modalities, Vascul Pharmacol 49 (2008), 63-70.
44. J.N. Peart, L.E. Hoe, G.J. Gross and J.P. Headrick, Sustained ligand-activated preconditioning via delta-opioid receptors, J Pharmacol Exp Ther 336 (2011), 274-281.
45. A. Prasad, G. Stone, D. Holmes and B. Gersh, Reperfusion Injury, Microvascular dysfunction, and cardioprotection: The 'Dark Side' of reperfusion, Circulation 120 (2009), 2105.
46. S.V. Rendig, J.D. Symons and E.A. Amsterdam, Effects of statins on myocardial and coronary artery response to ischemiareperfusion, Can J Physiol Pharmacol 81 (2003), 1064-1071. (Pubitemid 38045836)
47. R. Schulz, Pleiotropic effects of statins: Acutely good, but chronically bad? J Am Coll Cardiol 45 (2005), 1292-1294. (Pubitemid 40523152)
48. Y.-T. Shen, C. Depre, L. Yan, J.Y. Park, B. Tian, K. Jain, L. Chen, Y. Zhang, R.K. Kudej, X. Zhao, J. Sadoshima, D.E. Vatner and S.F. Vatner, Repetitive ischemia by coronary stenosis induces a novel window of ischemic preconditioning, Circulation 118 (2008), 1961-1969.
49. K. Shinmura, M. Nagai, K. Tamaki, M. Tani and R. Bolli, COX-2-derived prostacyclin mediates opioid-induced late phase of preconditioning in isolated rat hearts, Am J Physiol Heart Circ Physiol 283 (2002), H2534-H2543. (Pubitemid 35345960)
50. Z. Szilvassy, P. Ferdinandy, P. Bor, I. Jakab, J. Szilvassy, I. Nagy, J. Lonovics and M. Koltai, Loss of preconditioning in rabbits with vascular tolerance to nitroglycerin, Br J Pharmacol 112 (1994), 999-1001. (Pubitemid 24245395)
51. Z. Szilvassy, P. Ferdinandy, J. Szilvassy, I. Nagy, S. Karcsu, J. Lonovics, L. Dux and M. Koltai, The loss of pacing-induced preconditioning in atherosclerotic rabbits: Role of hypercholesterolaemia, J Mol Cell Cardiol 27 (1995), 2559-2569. (Pubitemid 26003185)
52. A. Tsuchida, R. Thompson, R.A. Olsson and J.M. Downey, The anti-infarct effect of an adenosine A1-selective agonist is diminished after prolonged infusion as is the cardioprotective effect of ischaemic preconditioning in rabbit heart, J Mol Cell Cardiol 26 (1994), 303-311. (Pubitemid 24199291)
53. A.M. Vogt, H. Ando, M. Arras and A. Elsasser, Lack of adenosine causes myocardial refractoriness, J Am Coll Cardiol 31 (1998), 1134-1141. (Pubitemid 28212518)
54. M.Wei, P. Xin, S. Li, J. Tao, Y. Li, J. Li, M. Liu,W. Zhu and A.N. Redington, Repeated remote ischemic postconditioning protects against adverse left ventricular remodeling and improves survival in a rat model of myocardial infarction, Circ Res 108 (2011), 1220-1225.
55. Y. Xuan, Y. Guo, Y. Zhu, H. Han, R. Langenbach, B. Dawn and R. Bolli, Mechanism of cyclooxygenase-2 upregulation in late preconditioning, J Mol Cell Cardiol 35 (2003), 525-537. (Pubitemid 36539458)
56. D.M. Yellon and J. Downey, Preconditioning the myocardium: From cellular physiology to clinical cardiology, Physiol Rev 83 (2003), 1113-1151. (Pubitemid 37222269)
57. E. Zvetkova, N. Antonova, I. Ivanov, Y. Savov and Y. Gluhcheva, Platelet morphological, functional and rheological properties attributable to addictions, Clin. Hemorheol. Microcirc. 45 (2010), 245-251.